Please use this identifier to cite or link to this item:
Title: Appropriate use of non-steroidal anti-inflammatory drugs in rheumatology: Guidelines from the Spanish Society of Rheumatology and the Mexican College of Rheumatology [Uso apropiado de los antiinflamatorios no esteroideos en reumatología: Documento de consenso de la Sociedad Española de Reumatología y el Colegio Mexicano de Reumatología]
Author: Segura, G.B.
Cruz, B.H.
Gobbo, M.
Arbeloa, A.L.
Paramo, M.S.
Estrada, L.T.
Gonzalez, J.F.D.
Morales, R.E.
Villegas, F.G.
Rodriguez, L.A.G.
Alvaro, J.M.-G.
Armengol, H.A.
Carmona, L.
Redondo, J.R.
Rios, L.V.
Issue Date: 2009
Abstract: Objective: to develop guidelines for the appropriate use of NSAIDs in rheumatology. Methods: we used a methodology modified from the one developed by RAND/UCLA. Two groups of panellists were selected, one by the CMR and another by the SER. Recommendations were proposed from nominal groups and the agreement to them was tested among rheumatologists from both societies by a tworound Delphi survey. The analysis of the second Delphi round supported the generation of the final set of recommendations and the assignment of a level of agreement to each of them. Systematic reviews of five recommendations in which the agreement was low or was divided were also carried out. Results: here we present recommendations for the safe use of NSAIDs in rheumatic diseases, based on the best available evidence, expert opinion, the agreement among rheumatologists, and literature review. The trend is to reduce the frequency, duration and dose of NSAIDs in favour of non-pharmacological measures, analgesic drugs or disease modifying drugs. In addition, the recommendations help to identify profiles for increased toxicity, with an emphasis on gastrointestinal and cardiovascular risks. The recommendations deal with the course of action and monitoring in different risk groups and in patients using antiplatelet or anticoagulant drugs. The overall level of agreement is high. Conclusions: the NSAIDs are safe and effective drugs for the treatment of rheumatic diseases. However, it is necessary to individualize its use according to their risk profile. Zapotitlán 2008 Elsevier España, S.L. All rights reserved.
Appears in Collections:Producción científica UdeG

Files in This Item:
There are no files associated with this item.

Items in RIUdeG are protected by copyright, with all rights reserved, unless otherwise indicated.